Naseralallah Lina, Noureddine Zahra, Ahmed Afif, Al Hail Moza, Koraysh Somaya
Department of Pharmacy, Hamad Medical Corporation, Doha, Qatar.
J Pharm Policy Pract. 2025 Apr 25;18(1):2450593. doi: 10.1080/20523211.2025.2450593. eCollection 2025.
To elucidate the role of clinical pharmacists in rehabilitation programmes by examining the type, severity, medications involved, and the level of acceptance of pharmacists' interventions.
A cross-sectional study was conducted at the Qatar Rehabilitation Institute (QRI) in Doha, Qatar. Clinical pharmacists' interventions and their underlying rationales were categorised by the type of intervention using a validated classification system. The severity of these interventions was assessed using the National Patient Safety Agency (NPSA) Risk Matrix. Linear regression and chi-square analyses were employed to examine the relationships between patient-related and medication-related characteristics and the pharmacist interventions.
A total of 3,807 clinical pharmacists' interventions involving 815 patients were collected and analysed. The majority of patients ( = 501, 61.5%) had three or more interventions. Findings indicated that most interventions were addressing pharmacological strategy ( = 1670, 43.9%) and drug quantity ( = 1166, 30.7%). The most frequently reported intervention subtypes included dose optimisation ( = 749, 19.7%), additional drug therapy ( = 673, 17.7%), and medication discontinuation ( = 476, 12.5%). Cardiovascular agents were involved in 37.1% of the interventions, followed by endocrine medications (17.1%) and centrally acting agents (11.7%). A significant proportion of interventions were deemed to have moderate severity (79.8%). Statistical analysis revealed a positive linear correlation between age and the number of interventions per patient ( < 0.001); with no significant difference in the severity of interventions between adult and elderly patients ( = 0.09).
This study highlights the diverse roles of clinical pharmacists in the rehabilitation field. The unique complexity of rehabilitation patients creates a challenging environment for clinical pharmacists, requiring adherence to fundamental practice principles while customising approaches to address individual patient needs. Further research is needed to assess the impact of these interventions on clinically significant outcomes.
通过检查临床药师干预措施的类型、严重程度、涉及的药物以及对药师干预的接受程度，以阐明临床药师在康复计划中的作用。
在卡塔尔多哈的卡塔尔康复研究所（QRI）进行了一项横断面研究。使用经过验证的分类系统，根据干预类型对临床药师的干预措施及其基本原理进行分类。使用国家患者安全局（NPSA）风险矩阵评估这些干预措施的严重程度。采用线性回归和卡方分析来检验患者相关特征和药物相关特征与药师干预之间的关系。
共收集并分析了涉及815名患者的3807项临床药师干预措施。大多数患者（n = 501，61.5%）接受了三项或更多干预。结果表明，大多数干预措施涉及药理学策略（n = 1670，43.9%）和药物剂量（n = 1166，30.7%）。最常报告的干预子类型包括剂量优化（n = 749，19.7%）、额外药物治疗（n = 673，17.7%）和停药（n = 476，12.5%）。37.1%的干预措施涉及心血管药物，其次是内分泌药物（17.1%）和中枢作用药物（11.7%）。很大一部分干预措施被认为具有中等严重程度（79.8%）。统计分析显示年龄与每位患者的干预次数之间存在正线性相关性（P < 0.001）；成人和老年患者之间干预措施的严重程度无显著差异（P = 0.09）。
本研究突出了临床药师在康复领域的多种作用。康复患者独特的复杂性为临床药师创造了具有挑战性的环境，要求在定制方法以满足个体患者需求的同时，遵守基本的实践原则。需要进一步研究来评估这些干预措施对临床显著结局的影响。
